12 Best Under-the-Radar Stocks to Buy According to Hedge Funds

Page 3 of 11

9. Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best under-the-radar stocks to buy according to hedge funds. On February 25, H.C. Wainwright reduced its price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) from $67 to $60 and maintained its Buy rating on the stock.

The company reported Q4 2025 revenue of $202.1 million, which fell short of the consensus estimate of $254.9 million. For the full year 2025, Corcept Therapeutics Incorporated (NASDAQ:CORT) reported a revenue of $761.4 million, which was below the company’s revised guidance range of $800 million to $850 million.

Corcept Therapeutics Incorporated (NASDAQ:CORT) said that new prescriptions increased 61% year-over-year in 2025. However, this growth resulted in only a 37% increase in actual tables sold. According to the company, this gap was because of capacity constraints at its previous specialty pharmacy.

Sales of Korlym were also affected as Corcept Therapeutics Incorporated (NASDAQ:CORT) transitioned to a new specialty pharmacy, Curant Rare. The transition started in November 2025 and was completed in January 2026.

The company provided full-year 2026 revenue guidance of $900 million to $1 billion, which suggests about 25% year-over-year growth at the midpoint. H.C. Wainwright said the lower price target reflects a more cautious pricing outlook for the Korlym franchise. The firm estimates Corcept Therapeutics Incorporated’s (NASDAQ:CORT) total revenue for 2026 at around $910 million, which is near the lower end of the company’s guidance.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage pharmaceutical company focused on developing treatments for a wide range of serious disorders through cortisol modulation.

Page 3 of 11